Core Viewpoint - The company plans to invest 100 million RMB in Hefei Lif Biological Technology Co., acquiring a 7.0175% stake, marking its entry into the high-end bio-based fiber sector [2][3]. Group 1: Investment Overview - The investment in Lif Biological represents a strategic move to enhance the company's competitiveness while expanding into emerging industries [3]. - Lif Biological is recognized as a pioneer in the research of furan-based materials, focusing on bio-based furan materials characterized by being environmentally friendly, low-carbon, and high-performance [3][4]. Group 2: Lif Biological's Market Position - Lif Biological is a leader in the domestic FDCA (Furan-2,5-dicarboxylic acid) industry, with its products exhibiting superior quality compared to competitors [4]. - The company has established the world's first 1,000-ton FDCA production line and plans to launch a 10,000-ton production line by 2025, with the 1,000-ton line achieving a product purity of 99.99% [4]. - Following the launch of the 10,000-ton line, the expected price of FDCA is projected to decrease to 50,000-60,000 RMB per ton by 2025, and further to 20,000-30,000 RMB per ton after 2027 [4]. Group 3: Applications of FDCA - FDCA can be used to synthesize various polymers, including polyesters, polyurethanes, and polyamides, and is also applicable in producing plasticizers and new semi-aromatic nylon [5]. - PEF (polyethylene furanoate), derived from FDCA, exhibits superior mechanical properties, heat resistance, and gas barrier properties compared to PET (polyethylene terephthalate), making it suitable for a wide range of applications, particularly in packaging [5].